kongres ASTRO

Important TTaRGeT Study Results Presented at the ASTRO 2026 Congress

Dr. hab. Maciej Harat, Prof. at Bydgoszcz University of Science and Technology (PBŚ), President-Elect of PTNO, presented the long-term results of the prospective phase II clinical trial TTaRGeT at the American Society for Radiation Oncology (ASTRO) congress in Boston.

The TTaRGeT study investigated stereotactic radiotherapy planned on the basis of FET-PET imaging, combined with TTFields therapy, in patients with recurrent glioblastoma (GBM).

The median overall survival (OS) from enrollment in the study was 16.8 months, and the 5-year OS rate was 20.9%. The best results were observed in patients with a small volume of the treated lesion. The treatment was well tolerated by patients.

Recruitment is currently ongoing for the TTaRGeT 2.0 study, which compares stereotactic radiotherapy planned using FET-PET imaging plus TTFields with TTFields therapy alone in patients with recurrent GBM.

The results of the TTaRGeT study are an important contribution to the treatment of brain tumors using modern methods such as stereotactic radiotherapy and TTFields combined with advanced imaging.

Abstract Highlights

Similar Posts